Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype
Summary: Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent...
Main Authors: | Laura Z. Vanags, PhD, Joanne T.M. Tan, PhD, Keyvan K. Galougahi, MD, PhD, Andreas Schaefer, MD, Steven G. Wise, PhD, Andrew Murphy, PhD, Ziad A. Ali, MD, PhD, Christina A. Bursill, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-04-01
|
Series: | JACC: Basic to Translational Science |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452302X17302905 |
Similar Items
-
Refractory In-Stent Restenosis Attributable to Eruptive Calcified Nodule
by: Hiroki Nakano, MD, et al.
Published: (2020-10-01) -
Stabilizing Peri-Stent Restenosis Using a Novel Therapeutic Carrier
by: Patrick H. Kee, MD, PhD, et al.
Published: (2020-01-01) -
Stent treatment for huge aneurysm of the common hepatic artery: A case report
by: Manat Zhakubayev, MD, et al.
Published: (2019-01-01) -
Strikingly Different Atheroprotective Effects of Apolipoprotein A-I in Early- Versus Late-Stage Atherosclerosis
by: Jamie Morton, MBBS, PhD, et al.
Published: (2018-04-01) -
Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
by: Nisha Ohri, MD, et al.
Published: (2016-01-01)